Allergan Announces FDA Approval of Avycaz (ceftazidime and avibactam) for Pediatric Patients

DUBLIN, March 18, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam),...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news